| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Not applicable. Bromoacetamido-PEG4-acid is a chemical linker used in PROTAC and ADC synthesis, not a pharmacologically active compound with a biological target.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [1]. ADC is made up of antibodies that are connected to ADC cytotoxins by an ADC linker [2].
Not applicable. As a PEG linker, Bromoacetamido-PEG4-acid does not possess intrinsic biological activity. Its utility is in chemical conjugation: the bromoacetamide group reacts with thiols for protein labeling, and the carboxylic acid can be activated for amide bond formation. The hydrophilic PEG spacer improves aqueous solubility. |
| ln Vivo |
Not applicable. This compound is a chemical linker used for in vitro conjugation. It does not have in vivo pharmacological activity.
|
| Enzyme Assay |
Not applicable. Bromoacetamido-PEG4-acid is not evaluated in enzyme/receptor binding assays. Its identity and purity (≥96%) are confirmed by HPLC, NMR, and mass spectrometry. The compound's reactivity with thiol-containing molecules can be assessed by conjugation efficiency studies using LC-MS or SDS-PAGE.
|
| Cell Assay |
Not applicable. This compound is used as a reagent in chemical synthesis for preparing PROTACs and ADCs. The resulting conjugates are tested in cell-based assays for target degradation or cytotoxicity, but the linker itself is not tested directly on cells. The compound is typically dissolved in DMSO or DMF for use in coupling reactions.
|
| Animal Protocol |
Not applicable. Bromoacetamido-PEG4-acid is not administered to animals as a standalone compound. When incorporated into ADCs or PROTACs, the final construct may be evaluated in animal models for efficacy and safety.
|
| ADME/Pharmacokinetics |
Not applicable. Bromoacetamido-PEG4-acid (molecular weight: 386.24, CAS: 1807518-67-7) is a research chemical with no therapeutic application. The PEG4 spacer provides optimal hydrophilicity and flexibility for bioconjugation. The compound is stable at room temperature for shipping and should be stored at -20°C for long-term preservation.
|
| Toxicity/Toxicokinetics |
Not applicable. As a chemical linker, Bromoacetamido-PEG4-acid has no pharmacological toxicity profile. Standard laboratory safety precautions apply. Avoid inhalation, skin contact, and eye exposure. No specific toxicological data are available for this research compound. Use appropriate personal protective equipment when handling.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
[2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |
| Additional Infomation |
Bromoacetamido-PEG4-acid is a versatile heterobifunctional linker used in both PROTAC and ADC development. It is a cleavable 4-unit PEG ADC linker and a PEG-based PROTAC linker. The compound enables the synthesis of targeted therapeutics for protein degradation and targeted cancer therapy. It is for research use only and not intended for diagnostic or therapeutic applications.
|
| Molecular Formula |
C13H24BRNO7
|
|---|---|
| Molecular Weight |
386.236164093018
|
| Exact Mass |
385.073
|
| CAS # |
1807518-67-7
|
| PubChem CID |
87177921
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
557.7±50.0 °C at 760 mmHg
|
| Flash Point |
291.1±30.1 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.494
|
| LogP |
-1.31
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
22
|
| Complexity |
292
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrCC(NCCOCCOCCOCCOCCC(=O)O)=O
|
| InChi Key |
LMFYGPXSVUULRZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H24BrNO7/c14-11-12(16)15-2-4-20-6-8-22-10-9-21-7-5-19-3-1-13(17)18/h1-11H2,(H,15,16)(H,17,18)
|
| Chemical Name |
3-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5891 mL | 12.9453 mL | 25.8906 mL | |
| 5 mM | 0.5178 mL | 2.5891 mL | 5.1781 mL | |
| 10 mM | 0.2589 mL | 1.2945 mL | 2.5891 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
